Clinuvel Pharmaceuticals (CUV) Investor Presentation summary

Strategic evolution and innovation

• Overcame skepticism and adversity to achieve first-in-class systemic photoprotective drug approval and profitability, with continued expansion into ACTH and PhotoCosmetics segments.

• Focused on melanocortin innovation, diversifying through peptides, delivery technologies, and self-financing five strategic pillars.

• Investments target SCENESSE® expansion, new indications, US generic market entry, next-gen formulations, in-house manufacturing, and complementary technology acquisitions.

Financial performance and resilience

• Maintained a debt-free position with cash reserves of A$198.2m as of December 2024.

• Achieved strong revenue (CAGR 38%), expense (CAGR 20%), and profit (CAGR 25.7%) growth from 2017–2024.

• Despite a -25% NPAT CAGR over 7 years, share price experienced significant volatility.

• Cash reserves and prudent financial management positioned to weather industry downturns and execute development plans.

Industry context and peer comparison

• Few direct peers remain in melanocortin space; cash is critical for survival and growth.

• Case studies highlight sector volatility, with several biopharma peers facing failed trials, restructurings, or acquisitions.

• Commercial and clinical success achieved against industry skepticism and adversity.